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Venous thromboembolism and mortality in
breast cancer: cohort study with systematic
review and meta-analysis
Umair T. Khan1,2, Alex J. Walker1,3, Sadaf Baig1, Tim R. Card1, Cliona C. Kirwan4 and Matthew J. Grainge1*
Abstract
Background: Breast cancer patients are at an increased risk of venous thromboembolism (VTE). However, current
evidence as to whether VTE increases the risk of mortality in breast cancer patients is conflicting. We present data
from a large cohort of patients from the UK and pool these with previous data from a systematic review.
Methods: Using the Clinical Practice Research Datalink (CPRD) dataset, we identified a cohort of 13,202 breast
cancer patients, of whom 611 were diagnosed with VTE between 1997 and 2006 and 12,591 did not develop VTE.
Hazard ratios (HR) were used to compare mortality between the two groups. These were then pooled with existing
data on this topic identified via a search of the MEDLINE and EMBASE databases (until January 2015) using a
random-effects meta-analysis.
Results: Within the CPRD, VTE was associated with increased mortality when treated as a time-varying covariate
(HR = 2.42; 95% CI, 2.13–2.75), however, when patients were permanently classed as having VTE based on presence
of a VTE event within 6 months of cancer diagnosis, no increased risk was observed (HR = 1.22; 0.93–1.60). The
pooled HR from seven studies using the second approach was 1.69 (1.12–2.55), with no effect seen when restricted
to studies which adjusted for key covariates.
Conclusion: A large HR for VTE in the time-varying covariate analysis reflects the known short-term mortality
following a VTE. When breast cancer patients are fortunate to survive the initial VTE, the influence on longer-term
mortality is less certain.
Keywords: Breast cancer, Venous thromboembolism, Pulmonary embolism, Deep vein thrombosis, Mortality,
Prognosis, Cohort study, Systematic review, Meta-analysis
Background
Breast cancer is the most common type of cancer
amongst women worldwide accounting for approxi-
mately 1.67 million new cases and 522,000 deaths in
2012 [1], and therefore imposes a considerable disease
burden on healthcare resources across the globe. The
association between cancer and venous thromboembol-
ism (VTE) which includes deep vein thrombosis (DVT)
and pulmonary embolism (PE) was first established more
than 10 decades ago by Trousseau [2]. A developing
body of evidence indicates changes in the hemostatic
system even when VTE is absent in cancer patients, with
a symbiotic relationship between the hemostatic system
and tumour cells [3].
It is reported that breast cancer patients are 3–4 fold
more likely to develop VTE compared with patients of
equivalent age without cancer [4, 5]. Our recent work
[6] and other studies [7–9] have shown that this risk is
accentuated further in breast cancer patients receiving
tamoxifen and chemotherapy up to 5-fold and 10-fold,
respectively. The association between the development
of VTE in patients with cancer and reduced overall sur-
vival was first evidenced in a seminal paper published in
2000 by Sorensen and colleagues which found that the
12-month survival rate was 3-times higher in cancer
patients without a VTE [10]. Subsequent research has
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reported similar findings for a variety of specific cancer
types suggesting that VTE could potentially be used a
marker for severe and more aggressive forms of cancers
[11–14]. Relevant data specific to women with breast
cancer, however, are still lacking.
VTE associated with breast cancer is a devastating
complication, which occurs among women with an
otherwise good health prognosis. By establishing the
extent to which a VTE influences prognosis, especially
longer-term, the implications of both prophylactic and
therapeutic anticoagulation on preventing mortality can
be more fully understood. We therefore present new
data from a UK based cohort study and pool this with
existing published and unpublished data in a systematic
review and meta-analysis to assess the risk of mortality
in breast cancer patients with VTE compared to those
without VTE.
Methods
A summary of this was work previously published as a
poster at the National Cancer Research Institute confer-
ence in 2015 [15].
Cohort study (clinical practice research Datalink, CPRD)
Study population
The study includes data from the CPRD, previously
known as the General Practice Research Database, until
April 2013. It contains population-based electronic health
data on about 8% of the UK population [16] which has
been prospectively collated from over 600 GP practices in
the UK from 1987 onwards. It is an anonymous database,
which collects information on patient demographics, clin-
ical diagnoses, treatments and outcomes amongst other
variables. Its population is considered to be broadly repre-
sentative of UK population in terms of age and sex struc-
ture [17] and its quality and completeness has been
validated in various studies [18, 19]. Use of these data was
approved by the CPRD Independent Scientific Advisory
Committee (ISAC, protocol number- 10_091). ISAC is a
non-statutory expert advisory body which provides a for-
mal review for requests to access data from the CPRD.
The data used in this paper are based on about 50% of
CPRD practices in England for which the data is linked
to the following: Hospital Episodes Statistics (HES), pro-
viding information on primary and secondary diagnoses
and inpatient procedures; National Cancer Intelligence
Network (NCIN), providing information on cancer diag-
noses; and Office of National Statistics (ONS), providing
information on dates and underlying causes of death.
We selected all women with a first breast cancer diagnosis
(ICD-10 code C50) using just the NCIN (cancer registry)
source from 1st April 1997 (the date from which linked
data were first available) until 31st December 2006. These
patients were followed up until they died, left a
participating CPRD practice or 31st December 2010,
whichever came first. We excluded women who were i)
under 18 years old at the time of diagnosis, ii) diagnosed
in the 1st year of registration at a participating CPRD
practice; iii) diagnosed with breast cancer outside the
CPRD and HES registration periods; iv) developed VTE
prior to first cancer diagnosis.
Exposure, outcome and covariates
VTE was established when a medical code for venous
thromboembolism (ICD 10; I26, I80-I82) in either or
both the CPRD and HES was supported by evidence of
an anticoagulant prescription or medical code providing
evidence of anticoagulation being recorded between
15 days before and 90 days after the VTE event date.
Only the first VTE event following the cancer diagnosis
was considered in this study. This algorithm for defining
VTE has been previously validated using primary care
data alone [20]. Information on all deaths, including
dates of death, were established from the linked ONS
mortality data which were available for all women in the
study cohort. Covariates included cancer stage which
was classified as either “local disease” (confined to the
breast), “regional disease” (axillary lymph node involve-
ment), “distant metastases” (any evidence of distant
metastases) or “unknown stage”. An individual comor-
bidity score excluding breast cancer (Charlson score)
was calculated from GP records and coded into three
levels (0,1–3,≥3). Other covariates (age, smoking status,
BMI, surgery, chemotherapy and endocrine therapy) are
defined in exactly the same way as in our previous paper
from this cohort [6].
Statistical analysis
Multivariate cox adjusted proportional hazard ratios
were calculated for the VTE group compared to control
group using ‘STATA 13’. The survival analysis was con-
ducted using time-varying covariate (TVC) analysis
where VTE status changed from “unexposed” to “ex-
posed” at the time a VTE was diagnosed to ensure haz-
ard ratios gave an accurate representation of the risk of
mortality as the patients’ VTE status changed. Survival
analysis started at the time of breast cancer diagnosis for
all women. A non-time-varying covariate analysis (nTVA)
was also conducted where women assumed the same “ex-
posure level” throughout the entire follow-up period.
Patients who developed VTE in the first 6 months after
diagnosis of breast cancer were defined as the VTE group
and these were compared with women who did not
develop VTE. Any woman who died in this 6 month ex-
posure period was excluded from the nTVA analysis. This
approach referred to as the “Landmark” approach [21] has
the advantage of excluding the potential for immortal time
bias [22]. Follow-up commenced at the end of the
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6 months exposure window, and subsequent mortality in
the VTE and non-VTE groups was compared using a cox
proportional hazards model. Both types of analysis (TVC
and nTVA) were adjusted for age, stage, grade, comorbid-
ity, tamoxifen treatment, smoking, body mass index, sur-
gery and chemotherapy.
Systematic review and meta-analysis
Data sources and searches
This review was carried out and reported in line with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) guidelines for the report-
ing of clinical trials and observational studies [23]. A
comprehensive search of OVID MEDLINE from 1946 to
January week 1, 2015 and EMBASE from 1974 to January
week 2, 2015 was carried out to identify published cohort
studies and conference abstracts (EMBASE only) which
provided survival data on breast cancer patients with VTE
(Additional file 1: Appendix 1). Search terms relating to
breast cancer and venous thromboembolism were adapted
from previous Cochrane Collaboration reviews [24–26]
and our earlier systematic review on cancer and throm-
bosis [27] whilst Scottish Intercollegiate Guidelines
Network (SIGN) validated terms were used as a filter for
observational studies in MEDLINE [28].
Study Selection.
Titles, abstracts and full texts were independently reviewed
by two authors; AJW, SB for MEDLINE studies identified
up until October 2012 and UTK, MJG for studies identified
via EMBASE and in an updated MEDLINE search carried
out in January 2015. Any discrepancies in decision for
inclusion or exclusion of a particular paper were resolved
by mutual discussion amongst the authors. The following
criteria were used in the inclusion and exclusion of papers:
Study Design: All cohort studies (retrospective and pro-
spective) published as either full text articles or published
conference proceedings in the English language were con-
sidered for inclusion. Where data appeared in the form of
a published abstract from a conference (within EMBASE),
they were assessed for inclusion in the same way as pub-
lished journal articles. Authors of conference abstracts
judged as being of relevance were contacted in an attempt
to obtain additional information both to determine poten-
tial inclusion of the study and obtain unpublished data if it
transpired the study met our inclusion criteria. Data from
randomised-controlled trials (RCTs) were excluded from
selection as it is not recommended practice to combine
data from observational studies and RCTs [29] and since
RCTs may not be representative of all cancer patients with
or without VTE as they usually contain a select group of
patients [30].
Participants: Studies containing women (18 years old
and above) with breast cancer were considered. Studies
containing patients with a mixture of cancer types were
excluded unless data were presented separately for
women with breast cancer. There were no restrictions
made on the basis of nationality or stage of disease.
Exposure: Studies with breast cancer patients who had
defined VTE as an exposure group were considered.
Studies where all patients had or developed VTE were
excluded as it would not be possible to explore the
impact of a VTE on mortality in this instance. VTE was
defined as patients with deep vein thrombosis (DVT),
pulmonary embolism (PE). Other types of VTE, such as
portal vein thrombosis and vena cava thrombosis were
included if data were combined with DVT and PE. We
did not include VTE events associated with venous-
catheter use so as not to introduce further heterogeneity
(as prognosis following these is likely to be different).
Outcome: The outcome was all cause mortality. Survival
data were only considered if papers presented hazard
ratios or Kaplan-Meier graphs comparing survival data be-
tween breast cancer patients with VTE (cases) and breast
cancer patients without VTE (controls).
Data extraction
Data extraction was performed independently by two
reviewers (either SB, MJG or UTK, MJG). For the in-
stance where hazard ratios were estimated from a
Kaplan-Meier plot, this was done independently using
the formula developed by Parmar et al. [31]. The average
readings of the two survival probabilities for the two re-
viewers at each time point was taken when discrepancies
occurred. Where data were presented in the form of
hazard ratios, the standard error was calculated for haz-
ard ratios from each paper using upper and lower confi-
dence intervals.
Statistical analysis
Hazard ratios were pooled under the assumption of ran-
dom effects [32] using ‘STATA 13’. Separate pooling of
results was carried out for studies conducting TVC ana-
lysis, where women changed from non-exposed to
exposed at the time they develop VTE during survival
follow-up and nTVA, where exposure groups were de-
fined in the beginning of the study and women remained
in the same group throughout follow-up. Sub-group
analyses were performed on studies, which conducted
nTVA to address heterogeneity: (1) Whether studies
were adequately adjusted for key confounders; (2)
Whether VTE occurred before or after cancer diagnosis.
With regards to (1), a study was judged to be adequately
adjusted if it adjusted for at least two of the three covari-
ates: (i) age, (ii) co-morbidity and/or performance status,
(iii) stage of breast cancer. Studies that did not meet the
criteria were classed as ‘non-adjusted’. With regards to
(2), where the VTE event occurred before cancer
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diagnosis for the majority of patients in the study; these
studies were grouped together and compared with stud-
ies where patients developed VTE after cancer diagnosis
to enable us to explore whether the time when the pa-
tients develop VTE influences mortality. Equivalent sub-
group analyses were not presented for studies conduct-
ing a TVC analysis due to the small number of studies
(n = 2) and homogeneity of results between these. Het-
erogeneity was assessed using the I-square statistic in all
instances.
Results
Cohort study (CPRD)
Study population
From the CPRD database, a total of 13,202 patients with
a new diagnosis of breast cancer were identified. In total,
611 women developed VTE during the study period
(cases) and these were compared with 12,591 women
who remained free from VTE (controls). The median
age was 62 years (IQR 52–74) and 3.6% of women with
VTE had distant metastases compared with 3.4% of
those without VTE (the corresponding figures with dis-
ease localized to the breast with no nodal involvement
were 38.3% and 35.2%; respectively). In total, 3504
(27.8%) women in the control group died during the
study period compared with 298 (48.8%) in the VTE
group. A comparison of the groups is summarized in
Table 1.
Survival analysis
Overall, the crude hazard ratio (HR) was 2.97 (95% CI
2.62–3.36) in the analysis where VTE was treated as a
time-varying covariate. The HR was 2.42 (95% CI 2.13–
2.75) after adjustment for covariates (Table 2). For pa-
tients with earlier stage of disease, the relative influence
of VTE on mortality was greater compared with those
for whom the disease had spread (adjusted HR 2.94
(95% CI 2.29–3.77 for local disease, 2.53 (95% CI 2.01–
3.19) for regional disease (axillary node involvement)
and 1.47 (95% CI 0.82–2.63) for distant metastases.
When results were stratified by comorbidity score into
three levels (Charlson score 0, 1–3, ≥4) there was no
notable difference in the magnitude of the HRs between
the three subgroups (Additional file 2: Table S1).
For the non-time varying covariate analysis (Table 2)
the unadjusted HR was significant, 1.63 (95% CI 1.24–
2.14), however after adjustment for the same covariates
listed above, this became non-significant, 1.22 (95% CI
0.93–1.60). Subsequent subgroup analysis for the various
stages of breast cancer reported no significant difference
in mortality between women with and without VTE in
any of the four subgroups (Table 2). The relationship
with mortality to the other covariates in these data is
summarised in Additional file 3: Table S2.
Systematic review and meta-analysis
Selection of studies
A total of 4085 search results were generated from our
search strategy and subsequently full text was obtained
for 70 articles. Out of a total of 70 full text articles, 8
were selected for the final review with the addition of
the CPRD data described above (Fig. 1). At the full text
stage, there were 15 studies which would have met the
inclusion criteria, except that they did not provide separ-
ate data on breast cancer patients. There were an add-
itional 8 studies which met the inclusion criteria except
that the survival data were presented in such a way that
hazard ratios could not be estimated. Two studies
Table 1 Summary of patient characteristics from the CPRD
Total No VTE % VTE %
12,591 611
Cancer stage Local disease 4823 38.3 214 35
Regional disease 2800 22.2 161 26.4
Distant metastases 449 3.6 21 3.4
Unknown 4519 35.9 215 35.2
Age (years) <40 694 5.5 21 3.4
40–49 1967 15.6 63 10.3
50–59 3154 25 108 17.7
60–69 2794 22.2 179 29.3
70–79 2249 17.9 158 25.9
80–89 1733 13.8 82 13.4
Charlson score 0 6692 53.1 295 48.3
1 to 3 5567 44.2 293 48
≥4 332 2.6 23 3.8
Current Smoking No 11,602 92.1 572 93.6
Yes 989 7.9 39 6.4
Body mass Index
(kg/m2)
Underweight
(<19)
188 1.5 4 0.7
Ideal (19.0–24.9) 3006 23.9 93 15.2
Overweight
(25.0–29.9)
2372 18.8 148 24.2
Obese (30.0–34.9) 1046 8.3 73 11.9
Morbidly obese
(≥35.0)
402 3.2 38 6.2
Missing 5577 44.3 255 41.7
Surgery No 2989 23.7 104 17
Yes 9602 76.3 507 83
Chemotherapy No 10,007 79.5 422 69.1
Yes 2584 20.5 189 30.9
Endocrine therapy No 2232 17.8 87 14.2
Yes 10,316 82.2 524 85.8
Died No 9087 72.2 313 51.2
Yes 3504 27.8 298 48.8
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published in the form of conference abstracts met all cri-
teria for inclusion (from a total of 6 authors contacted),
from which the authors supplied unpublished data, and
provided consent for their data to be included in the
study [33, 34].
Overview of included studies
Characteristics of individual included studies are in
Additional file 4: Table S3. Overall, from the 8 included
studies, 4 were from UK, 2 from USA, and 1 from Mexico
and 1 from Brazil. Average age (median or mean) from
the included studies ranged from 51 to 75 years. The me-
dian follow-up of studies (where available) ranged from
15.4 to 26.2 months. Two studies ([35]; CPRD) used a
TVC analysis whereas the rest used nTVA. Out of the
studies using nTVA, 3 studies ([9, 36]; CPRD) were
adequately adjusted whereas 4 studies [33, 34, 37, 38] were
classified as unadjusted as they did not meet our criterion
for adjustment even though some studies had adjusted for
other covariates [33, 37]. Furthermore, from the nTVA
group, 5 studies defined VTE as occurring after cancer
diagnosis ([9, 33, 34, 38]; CPRD) and 2 studies [36, 37]
defined VTE occurring prior to diagnosis.
Random-effects meta-analysis
When results from our cohort (CPRD) were pooled with
one other study [35] which treated VTE as a TVC, the
pooled HR for risk of mortality in breast cancer patients
with VTE was 2.35 (95% CI 2.17–2.55) and heterogeneity
was minimal. In a pooled analysis of results from seven
studies (including the CPRD), which utilized nTVA, the
overall hazard ratio was 1.69 (95% CI 1.12–2.55),
however, heterogeneity was substantial (I-square = 89%,
Fig. 2).
The pooled HR from 4 studies which were unadjusted
(or inadequately adjusted) was 2.37 (95% CI 1.26–4.46),
in contrast to the 3 studies which had adequately
adjusted for covariates, no increase in mortality was
observed among patients with VTE [HR 1.11 (95% CI
0.92–1.34)], highlighting that the risk of mortality in
breast cancers due to VTE was non-significant when
adjusted for important covariates including age, stage
and comorbidity (or performance status) (Fig. 3).
Table 2 Results from CPRD (time-varying and non-time-varying covariate analysis by adjustment)
Time-Varying (follow-up from cancer diagnosis)
Unadjusted Adjusted for age Multivariate Modela
No. of patients No. Died HR 95% CI HR 95% CI HR 95% CI
All patients No VTE 12,591 3504 1 1 1
VTE 611 298 2.97 2.62 3.36 2.58 2.27 2.92 2.42 2.13 2.75
Local disease No VTE 4823 726 1 1 1
VTE 214 81 4.05 3.17 5.16 3.21 2.51 4.1 2.94 2.29 3.77
Regional disease No VTE 2800 798 1 1 1
VTE 161 89 3.23 2.57 4.05 2.9 2.31 3.64 2.53 2.01 3.19
Distant metastases No VTE 449 300 1 1 1
VTE 21 14 1.4 0.8 2.47 1.27 0.72 2.24 1.47 0.82 2.63
Unknown stage No VTE 4519 1680 1 1 1
VTE 215 114 2.45 2 3.01 2.27 1.85 2.78 2.33 1.89 2.87
Non-time-varying (follow-up commencing 6 months after cancer diagnosis)
All patients No VTE 12,148 3171 1 1 1
VTE 138 54 1.63 1.24 2.14 1.50 1.15 1.96 1.22 0.93 1.60
Local disease No VTE 4854 743 1 1 1
VTE 45 11 1.72 0.95 3.12 1.51 0.83 2.74 1.25 0.68 2.27
Regional disease No VTE 2834 834 1 1 1
VTE 46 22 1.73 1.13 2.64 1.53 1 2.34 1.17 0.76 1.79
Distant metastases No VTE 331 212 1 1 1
VTE 5 3 1.34 0.43 4.18 1.37 0.44 4.3 1.32 0.40 4.35
Unknown stage No VTE 4129 1382 1 1 1
VTE 42 18 1.37 0.86 2.18 1.34 0.84 2.14 1.23 0.77 1.96
aage plus: stage (where not stratified), grade, comorbidity, tamoxifen therapy, smoking, body mass index, surgery and chemotherapy. In the time-varying analysis,
no. died represents the number of deaths in women who never developed VTE
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A second sub-group analysis was carried out on studies
using nTVA by whether VTE occurred prior to cancer
diagnosis or after it. The pooled HR for the 5 studies de-
fining VTE after cancer diagnosis was 1.70 (95% CI 1.07–
2.71) compared to the 2 studies which defined VTE before
cancer diagnosis [HR 1.63 (95% CI 0.64–4.13)] (Fig. 4).
Discussion
Summary of findings
Based on data from a large cohort of women with breast
cancer representative of the United Kingdom, the risk of
mortality was more than doubled in the time following a
VTE event, reflecting the high short-term mortality fol-
lowing a thromboembolic event. In contrast, using the
landmark approach which assigned women as being a
VTE or non-VTE case for the entire follow-up period,
VTE exerted no increased risk of mortality once import-
ant covariates such as stage of disease and a measure of
overall health status was taken into account. When our
data were pooled with those from seven additional studies
(including two which are currently unpublished), the
pooled hazard ratio was 2.35 (2.17–2.55) for studies using
a TVC analysis and 1.69 (1.12–2.55) for those using an
nTVA, the latter of which contained substantial hetero-
geneity. The hazard ratio we report for TVC analysis is
comparable to that reported by Posch et al. more recently
of 2.98 (2.36–3.77) using a multi-state model applied to
data from the Vienna Cancer and Thrombosis Study
which considered all cancer types rather than breast can-
cer specifically [39]. Sub-group analyses reported higher
HRs in studies which did not adjust for key covariates,
whereas the timing of VTE diagnosis in relation to the
cancer diagnosis did not have an appreciable impact on
the magnitude of the hazard ratios observed.
Strengths and limitations of the research
To our knowledge, this is the first attempt to systematically
evaluate all available data exploring whether or not among
Fig. 1 Summary of search results and breakdown at each stage. CA conference abstracts
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women with breast cancer, the risk of mortality is raised fol-
lowing development of a VTE. Our systematic review was
strengthened by inclusion of two established databases
(MEDLINE and EMBASE) with carefully selected search
terms. Furthermore, through obtaining additional data for
studies originally published in the form of conference
abstracts, we were able to include data which is currently
unpublished in our synthesis of the evidence. Thirdly, by
inclusion of our data from the CPRD we were able to in-
clude data in the overall synthesis which has the strength of
utilizing recently linked primary, secondary and cancer
registration data from a large representative sample of
women from the UK. Our two distinct approaches to ana-
lysis, enabled us to assess the effect of a VTE on short-term
and long-term mortality separately.
Limitations of our work include the fact the methods
of meta-analysis employed in our systematic review re-
lied on survival data being presented both separately for
breast cancer patients in studies where patients with a
mixture of cancer types were reported, and also in an
appropriate numerical form so that hazard ratios (and
standard errors or confidence intervals) from these
could be obtained. As such there were several potentially
relevant studies which have been conducted but which
we were unable to include. Our systematic review also
contained a high degree of heterogeneity, meaning that
it was not possible for us to determine the “true” degree
which developing a VTE has on subsequent mortality.
Instead effect sizes would be influenced by characteris-
tics of the study population (age, tumour characteristics
Time-varying covariate
Chew (2007)
CPRD (2015)
Subtotal
Non-time-varying covariate
Gross (2007)
Jones (2009)
Paneesha (2009)
Kirwan (2011)
Reboucas (2015)
CPRD (2015)
Caserman-Maus (2015)
Subtotal
Author
2.30 (2.07, 2.56)
2.42 (2.13, 2.75)
2.35 (2.17, 2.55)
1.01 (0.77, 1.33)
2.61 (2.09, 3.26)
3.02 (1.20, 7.61)
1.18 (0.47, 2.95)
1.10 (0.83, 1.46)
1.22 (0.93, 1.60)
4.60 (2.31, 9.15)
1.69 (1.12, 2.55)
HR (95% CI)
(I-squared=0.0%)
(I-squared=88.2%)
.25 .5 1 2 4 8 16
Hazard Ratio of Death
Fig. 2 Forest plot of the hazard ratios by type of analysis, time-varying covariate compared to non-time-varying
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and treatment modalities), methods for establishing VTE
(including whether methods such as a Doppler scan
were used to confirm the diagnosis) and duration of
follow-up. In part, we were successful in elucidating spe-
cific reasons for this heterogeneity, namely that our find-
ing in the CPRD that effect sizes were attenuated
considerably after adjustment for key covariates was also
demonstrated within one of the papers included in our
systematic review [36]. However, even in sub-group ana-
lyses whereby data were stratified by factors, which we
anticipated, would account of heterogeneity of results
between studies, considerable residual heterogeneity
remained in many instances (as indicated by the I-
square statistic). Finally, our findings could be influenced
by the potential for publication bias as is inherent with
any systematic review. However, in the present review
no obvious differences were found in the magnitude of
the effect size between the five studies currently pub-
lished and three presently unpublished.
Differences in methodological quality of original stud-
ies represent another potential source of heterogeneity
in reviews of observational studies as addressed by the
sub-group analyses described above. Similarly, methodo-
logical deficiencies in some or all of the component
studies could bias estimates of the pooled result. Many
of the source studies relied on routinely collected ad-
ministrative data for determining VTE status in study
participants. Misclassification of VTE events could at-
tenuate the magnitude of an association between VTE
and survival. In the CPRD, our algorithm for defining
Overall
Subtotal
Jones (2009)
Gross (2007)
Reboucas (2015)
Subtotal
Non-adjusted
CPRD (2015)
Paneesha (2009)
Caserman-Maus (2015)
Kirwan (2011)
Adjusted
Author
1.69 (1.12, 2.55)
2.37 (1.26, 4.46)
2.61 (2.09, 3.26)
1.01 (0.77, 1.33)
1.10 (0.83, 1.46)
1.11 (0.92, 1.34)
1.22 (0.93, 1.60)
3.02 (1.20, 7.61)
4.60 (2.31, 9.15)
1.18 (0.47, 2.95)
HR (95% CI)
(I-squared=0.0%)
(I-squared=89.6%)
(I-squared=88.2%)
.25 .5 1 2 4 8 16
Hazard Ratio of Death
Fig. 3 Forest plot of the hazard ratios of nTVA studies comparing adjusted to non-adjusted studies
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VTE was previously shown to have positive predictive
value of 84% when compared with more detailed investi-
gations of patient records [20]. However, this algorithm
has not been validated specifically in cancer patients and
would not capture anticoagulant prescriptions emanat-
ing from secondary care. In studies which did not use a
TVC approach, the complex nature of the chronology
between diagnosis of VTE, diagnosis of cancer and sub-
sequent outcome could influence findings. For example,
it is common for studies to start follow-up at the time of
cancer diagnosis. If VTE occurs after this date then there
would be a period of guaranteed follow-up time between
the cancer and VTE dates, which would create a
favourable impression of survival in this “exposed” group
and thus weaken any true association (immortal time
bias). Whilst we attempted to stratify results by timing
of VTE and cancer, this information could not always be
adequately established from the original study reports.
The potential for immortal time bias was avoided in
both of the approaches to analysis we adopted for the
CPRD data. The use of a time-varying covariate analysis
incorporates changes in exposure status throughout the
follow-up period and thus is sensitive to picking up
changes in risk of outcome which occur shortly after a
change in exposure status [40]. This approach is sup-
ported by the recent EPIPHANY study findings which
reported fatality percentages following a pulmonary
embolism of 14% at 30 days and 27% at 90 days follow-
up in 1033 cancer patients [41]. Therefore, the Landmark
approach excludes a relatively high percentage of all VTE-
Overall
Subtotal
Jones (2009)
Kirwan (2011)
Subtotal
CPRD (2015)
Paneesha (2009)
Reboucas (2015)
Author
Gross (2007)
VTE before cancer diagnosis
Caserman-Maus (2015)
VTE after cancer diagnosis
1.69 (1.12, 2.55)
1.63 (0.64, 4.13)
2.61 (2.09, 3.26)
1.18 (0.47, 2.95)
1.70 (1.07, 2.71)
1.22 (0.93, 1.60)
3.02 (1.20, 7.61)
1.10 (0.83, 1.46)
HR (95% CI)
1.01 (0.77, 1.33)
4.60 (2.31, 9.15)
(I-sqaured=77.4%)
(I-squared=96.4%)
(I-sqaured=88.2%)
.25 .5 1 2 4 8 16
Hazard Ratio of Death
Fig. 4 Forest plot of the hazard ratios of nTVA studies comparing ‘VTE before cancer diagnosis’ with ‘VTE after cancer diagnosis’
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related deaths and is more appropriate for assessing mor-
tality longer term in patients who survive the initial event.
The analysis also has some more favourable statistical
properties as the alternative approach used (landmark
analysis) does not include VTE events which occur after
6 months in addition to the exclusion of the 6-months fol-
lowing cancer diagnosis from the follow-up time However,
this approach does have limitations especially when using
routine healthcare data, as in the case of mortality as an
outcome, acute medical events are more likely to get diag-
nosed in the intensive period of medical consultation
which is known to take place in the weeks prior to death.
In this particular context, however, the key advantage of
the landmark approach is that it allows us to interpret
how a VTE event occurring relatively soon after diagnosis
(when the risk of VTE is highest) influences mortality lon-
ger term for which the clinical implications may be more
apparent.
Finally we were unable to clearly establish whether fac-
tors such as cancer stage and underlying health status
may have influenced the extent to which a VTE is asso-
ciated with the risk of mortality. Whilst HRs were larger
for women with local disease at the time of diagnosis,
given that the risk of mortality was considerably higher
in women with metastatic disease (314 deaths in 1200
person-years of follow-up) than in women with local dis-
ease (807 deaths in 32,000 person-years of follow-up)
this is likely to be due to the issue of scale dependence
whereby there is the potential for VTE to have a greater
impact on a measure of relative association (such as the
hazard ratio) in subgroups where the underlying risk of
an outcome event is lower [42].
Clinical implications
There are several mechanisms via which a VTE may exert
a detrimental impact on cancer survival. There is an im-
mediate impact due to the known high short-term fatality
resulting from a thrombotic event which among all pa-
tients is estimated to be around 1% following a DVT and
over 20% following a pulmonary embolism [41, 43].
Pooled results from two studies from the US and UK
which would capture this short-term effect through in-
corporating VTE as a time-varying covariate indicate a
greater than 2-fold of risk of mortality following a VTE.
Compliance with existing clinical guidelines on primary
prevention of VTE in cancer patients which advise target-
ing of prophylaxis in selected patients undergoing cancer
surgery along with some patients in the outpatient setting
[44–46]. However, it should be noted that in the Khorana
score women with breast cancer may not be recom-
mended for primary prophylaxis as these tend to score
poorly on cancer type, anaemia and thrombocytosis. We
have previously shown with this cohort that VTE events
in women with breast cancer are likely to occur either
during or immediately following chemotherapy or in the
first month following surgery [6].
Cancer patients are at increased risk of bleeding from
anticoagulation, with an estimated 2-fold increased risk
for major bleeding compared to non-cancer patients
[47]. Unsurprisingly, major and minor bleeding increases
the hazard of death by over two-fold [48]. In addition,
cancer patients are at 2–3 fold increased risk of recur-
rent VTE [47, 49–51]. However, based on the data from
the current study, in the case where a woman with
breast cancer is fortunate enough to survive her initial
thrombotic event, the influence on long term prognosis
is more difficult to establish, with a suggestion from this
current study that mortality is not raised at all once can-
cer stage and underlying health status are taken into
account. Guidelines from the UK National Institute of
Health and Care Excellence (NICE) along with equiva-
lent guidelines from other countries advise that cancer
patients who develop VTE should receive at least
6 months of anticoagulation and in some instances treat-
ment should continue indefinitely [52]. It is plausible to
suggest that if adherence to these guidelines is good,
then this could at least in part explain the relatively
promising prognosis for women with breast cancer who
survive their VTE, with prophylactic anticoagulation
successfully mitigating against recurrent VTE (a likely
cause of mortality). However the current NICE guide-
lines were not as robust in the era covered by the CPRD
data and studies included in our meta-analysis. A move
from vitamin-K antagonists to low molecular weight
heparins in recent years because of greater efficacy in
preventing recurrent VTE may further negate the nega-
tive survival impact of recurrent VTE [53]. More con-
temporary data reporting rates of VTE recurrence in
cancer patients from the last decade as well as those
with specific types of cancer are needed.
A further explanation for the detrimental impact of
VTE on cancer survival relates to complex mechanisms
underlying the symbiotic relationship between coagula-
tion and tumour factors. Coagulation parameters are
understood to play an important role in tumour progres-
sion and metastases, with changes in the haemostatic
system evident in cancer patients even in the absence of
a VTE [3]. It is hypothesized that VTE, even at the sub-
clinical level of biochemical hypercoagulability, may have
a role in promoting cancer growth and metastases and
be associated with a more aggressive tumour behavior
[54]. This has led researchers over many decades to
explore the antineoplastic effects of anticoagulants and
whether they could improve cancer survival even in the
absence of a VTE. Overviews of the most recent ran-
domized trial data comprising cancer patients without
indication for anticoagulation (usually cancer outpa-
tients) found no evidence of both oral anticoagulation
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(warfarin) [25] and low molecular weight heparin [50]
on mortality at 12 months. However, evidence from the
LMWH review indicates that this intervention does have
modest (16%) reduction in longer term mortality, in line
with previous evidence that the beneficial effects of
LMWH occur after 12 months and also in patients with
less advanced disease [51]. It is possible that if barriers
to adherence with long term LMWH use could be over-
come then there is the potential for a greater reduction
mortality risks in cancer patients both with and without
a previous VTE [55]. The current consensus is that fu-
ture research in this area should focus on patients with
specific cancer types rather than heterogeneous groups
of tumours [3, 51].
Conclusion
We report evidence that short-term mortality is raised
in women with breast cancer following a VTE. However,
when women are fortunate enough to survive their ini-
tial VTE event, the influence on mortality is far less cer-
tain due to considerable variability in results between
individual studies. Future observational research on this
topic should explore this heterogeneity by discovering
whether there are specific groups of women with breast
cancer for whom a VTE may exert a particularly poor
prognostic effect, and for whom treatment strategies
could therefore be influenced. Only with this knowledge
along with more relevant data specific to women with
breast cancer can we fully start to understand the true
extent that deaths in breast cancer patients can be pre-
vented by primary prophylaxis in those most at risk and
whether presence of a VTE could influence cancer treat-
ment strategies in these patients.
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